Cologuard growth accelerates to $48.4 million in revenue during first quarter; volume grows 150 percent year over year to 100,000 completed tests

  • Gross margin expands to 65 percent during first quarter
  • Revenue guidance raised to $195-205 million for 2017, from $170-180 million;
  • Guidance for completed Cologuard tests increased to at least 470,000 tests, from at least 415,000;
  • 10,000 additional providers ordered Cologuard during the first quarter, and insurance coverage expanded to 78 percent.

MADISON, Wis., April 27, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenues of $48.4 million and completed approximately 100,000 Cologuard tests during the quarter ended March 31, 2017. First-quarter 2017 revenues and completed Cologuard test volume grew 226 percent and 150 percent from the same period of 2016, respectively.

Read More

Topics: Investor Relations

CMS includes Cologuard in updated Medicare Advantage Star Ratings

 

 

MADISON, Wis., April 4, 2017 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) included Cologuard® in its updated Medicare Advantage Star Ratings program. Medicare Advantage plans now can help increase their Star Ratings when their beneficiaries complete Cologuard, Exact Sciences' non-invasive colon cancer screening test. 
 
Read More